help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alexandersen, P.
Right arrow Articles by Christiansen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alexandersen, P.
Right arrow Articles by Christiansen, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 9 3013-3020
Copyright © 1999 by The Endocrine Society


Original Studies

Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study1

Peter Alexandersen, Bente Juel Riis and Claus Christiansen

Center for Clinical & Basic Research, DK-2750 Ballerup, Denmark

Address all correspondence and requests for reprints to: Peter Alexandersen, Center for Clinical & Basic Research, Ballerup Byvej 222, DK-2750 Ballerup, Denmark. E-mail: pa{at}ccbr.dk

Sodium fluoride stimulates bone formation and has been used to treat osteoporosis for decades despite debate about the antifracture efficacy. Hormone replacement therapy (HRT) results in only modest increases in bone mineral density (BMD). However, for women with low bone mass, the ideal therapy should not only inhibit bone resorption but simultaneously stimulate bone formation to increase bone mass above the fracture threshold. We thus performed a randomized, double-blind, placebo-controlled intervention study to prospectively investigate the effect of a low dose of fluoride, in combination with HRT, on BMD and biochemical markers of bone turnover.

One hundred healthy postmenopausal women (60–70 yr old) were thus randomly assigned to: 1) HRT [transdermal 17ß-estradiol, releasing 50 µg/day; plus oral norethisterone acetate (NETA), 1 mg/day]; or 2) oral monofluorophosphate (MFP; equivalent to fluoride, 20 mg/day); or 3) HRT+MFP; or 4) placebo, for 96 weeks. All participants received a calcium supplement of 1000 mg/day. Sixty-eight women completed the study.

We found a pronounced, linear increase in spinal BMD during treatment with HRT+MFP [11.8% (1.7% SEM)], which was significantly greater than the increase in the HRT group [4.0% (0.5% per yr); P < 0.05]. MFP produced a smaller increase [2.4% (0.6% per yr)], whereas there was no change in the placebo group [0.0% (0.5% SEM)]. Similar changes were found at the other skeletal sites (distal forearm, hip, and total body). Markers of bone formation showed a fall in the HRT group, which was significantly more pronounced than in the combined HRT+MFP group. A nonsignificant increase was found in the MFP group, whereas the placebo group showed a decrease caused by calcium treatment. The marker of bone resorption decreased significantly more in the HRT and the HRT+MFP groups than in the placebo group but tended to increase in the MFP group.

In conclusion, this study shows, by use of biochemical markers of bone turnover, that bone resorption and formation may be dissociated, as a result of actions of two compounds with diverging effects on bone turnover. Furthermore, the synergistic effects of relatively low doses of the compounds suggested statistically and clinically significant increases in trabecular and probably also cortical bone. Adverse effects were relatively rare and mild.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
I. R. Reid, T. Cundy, A. B. Grey, A. Horne, J. Clearwater, R. Ames, B. J. Orr-Walker, F. Wu, M. C. Evans, G. D. Gamble, et al.
Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2446 - 2452.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Doren, J.-A. Nilsson, and O. Johnell
Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis
Hum. Reprod., August 1, 2003; 18(8): 1737 - 1746.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell, and A. Cranney
V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women
Endocr. Rev., August 1, 2002; 23(4): 529 - 539.
[Full Text] [PDF]


Home page
JAMAHome page
D. J. Torgerson and S. E. M. Bell-Syer
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials
JAMA, June 13, 2001; 285(22): 2891 - 2897.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society